Alnara raises $35 million as non-porcine PERT nears NDA filing
This article was originally published in Scrip
Executive Summary
Alnara Pharmaceuticals has raised $35 million in a series B financing round. The proceeds will be used to advance its lead programme liprotamase, an oral non-porcine recombinant-derived pancreatic enzyme replacement therapy (PERT) which has completed Phase III development in collaboration with the Cystic Fibrosis Foundation. The US company expects to file the NDA with the US FDA in the first quarter.